Moreover, treatments such as Tanreqing (TRQ) and fluvoxamine effectively inhibit the release of inflammatory factors and reduce the level of pulmonary fibrosis by targeting the cGAS-STING signaling pathway (32–34). Here, STING1 is linked to pulmonary fibrosis.